アジソン病治療の世界市場2019-2023

【英語タイトル】Global Addison's Disease Therapeutics Market 2019-2023

Technavioが出版した調査資料(IRTNTR31202)・商品コード:IRTNTR31202
・発行会社(調査会社):Technavio
・発行日:2019年4月26日
・ページ数:118
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、アジソン病治療の世界市場について調査・分析し、市場概要、市場環境、アジソン病治療市場規模、製品別(経口剤、非経口剤)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・アジソン病治療の世界市場概要
・アジソン病治療の世界市場環境
・アジソン病治療の世界市場動向
・アジソン病治療の世界市場規模
・アジソン病治療の世界市場:業界構造分析
・アジソン病治療の世界市場:製品別(経口剤、非経口剤)
・アジソン病治療の世界市場:地域別市場規模・分析
・アジソン病治療の北米市場規模・予測
・アジソン病治療のヨーロッパ・中東・アフリカ市場規模・予測
・アジソン病治療のアジア太平洋市場規模・予測
・アジソン病治療の主要国分析
・アジソン病治療の世界市場:意思決定フレームワーク
・アジソン病治療の世界市場:成長要因、課題
・アジソン病治療の世界市場:競争環境
・アジソン病治療の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market

The favorable reimbursement scenario is one of the key factors expected to trigger the market growth during the forecast period. Reimbursement is quite essential for ensuring wider patient access to the Internet. Insurers are increasingly providing complete reimbursement for most of the drugs indicated for the treatment of adrenal insufficiency. In addition, governments and healthcare agencies are further investing a huge amount of money in improving national or regional health. As a result, the supporting reimbursement policies are expected to contribute significantly to the Addison’s disease therapeutics market growth during the forecast period. Technavio’s analysts have predicted that the Addison’s disease therapeutics market will register a CAGR of nearly 4% by 2023.

Market Overview

Special drug designations

Special drug designations promote vendors to come up with better drugs in the market, which extends the product offerings to patients and their adherence to therapeutic alternatives. This, in turn, drives the market growth.

Adverse effects associated with available drugs

The drugs that are available in the market include glucocorticoids and mineralocorticoids, which are associated with harmful side effects. These side effects exert a negative impact on the quality of life of the patients and reduce their willingness to continue treatment with the drugs.

For the detailed list of factors that will drive and challenge the growth of the Addison’s disease therapeutics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. Various companies are focusing on investing in R&D of the medicines for curing rare and orphan diseases, including Addison’s disease, along with the chronic illnesses such as central nervous system (CNS) disorders, and cancer. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Oral drugs – Market size and forecast 2018-2023

Parenteral drugs – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Bristol-Myers Squibb Company

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Takeda Pharmaceutical Company Limited

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of vendors classification

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global rare diseases therapeutics market

Exhibit 02: Segments of global rare diseases therapeutics market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Product – Market share 2018-2023 (%)

Exhibit 18: Comparison by product

Exhibit 19: Oral drugs – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Oral drugs – Year-over-year growth 2019-2023 (%)

Exhibit 21: Parenteral drugs – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Parenteral drugs – Year-over-year growth 2019-2023 (%)

Exhibit 23: Market opportunity by product

Exhibit 24: Customer landscape

Exhibit 25: Market share by geography 2018-2023 (%)

Exhibit 26: Geographic comparison

Exhibit 27: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 28: North America – Year-over-year growth 2019-2023 (%)

Exhibit 29: Top 3 countries in North America

Exhibit 30: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 32: Top 3 countries in Europe

Exhibit 33: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in Asia

Exhibit 36: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in ROW

Exhibit 39: Key leading countries

Exhibit 40: Market opportunity

Exhibit 41: Reformulated corticosteroids

Exhibit 42: Impact of drivers and challenges

Exhibit 43: Vendor landscape

Exhibit 44: Landscape disruption

Exhibit 45: Vendors covered

Exhibit 46: Vendor classification

Exhibit 47: Market positioning of vendors

Exhibit 48: Bristol-Myers Squibb Company – Vendor overview

Exhibit 49: Bristol-Myers Squibb Company – Business segments

Exhibit 50: Bristol-Myers Squibb Company – Organizational developments

Exhibit 51: Bristol-Myers Squibb Company – Geographic focus

Exhibit 52: Bristol-Myers Squibb Company – Key offerings

Exhibit 53: Merck & Co. Inc. – Vendor overview

Exhibit 54: Merck & Co. Inc. – Business segments

Exhibit 55: Merck & Co. Inc. – Organizational developments

Exhibit 56: Merck & Co. Inc. – Geographic focus

Exhibit 57: Merck & Co. Inc. – Segment focus

Exhibit 58: Merck & Co. Inc. – Key offerings

Exhibit 59: Novartis AG – Vendor overview

Exhibit 60: Novartis AG – Business segments

Exhibit 61: Novartis AG – Organizational developments

Exhibit 62: Novartis AG – Geographic focus

Exhibit 63: Novartis AG – Segment focus

Exhibit 64: Novartis AG – Key offerings

Exhibit 65: Pfizer Inc. – Vendor overview

Exhibit 66: Pfizer Inc. – Business segments

Exhibit 67: Pfizer Inc. – Organizational developments

Exhibit 68: Pfizer Inc. – Geographic focus

Exhibit 69: Pfizer Inc. – Segment focus

Exhibit 70: Pfizer Inc. – Key offerings

Exhibit 71: Takeda Pharmaceutical Company Limited – Vendor overview

Exhibit 72: Takeda Pharmaceutical Company Limited – Business segments

Exhibit 73: Takeda Pharmaceutical Company Limited – Organizational developments

Exhibit 74: Takeda Pharmaceutical Company Limited – Geographic focus

Exhibit 75: Takeda Pharmaceutical Company Limited – Key offerings

Exhibit 76: Validation techniques employed for market sizing

Exhibit 77: Definition of vendors classification



【掲載企業】

Bristol-Myers Squibb Company、Merck & Co. Inc.、Novartis AG、Pfizer Inc.、Takeda Pharmaceutical Company Limited

★調査レポート[アジソン病治療の世界市場2019-2023] (コード:IRTNTR31202)販売に関する免責事項を必ずご確認ください。
★調査レポート[アジソン病治療の世界市場2019-2023]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆